- Home
- MTAL vs RCUS Comparison
MTAL vs RCUS Comparison
Compare MTAL & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTAL
- RCUS
- Stock Information
- Founded
- MTAL 2021
- RCUS 2015
- Country
- MTAL Jersey
- RCUS United States
- Employees
- MTAL N/A
- RCUS N/A
- Industry
- MTAL Blank Checks
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- MTAL Finance
- RCUS Health Care
- Exchange
- MTAL Nasdaq
- RCUS Nasdaq
- Market Cap
- MTAL 997.3M
- RCUS 906.4M
- IPO Year
- MTAL 2021
- RCUS 2018
- Fundamental
- Price
- MTAL $12.05
- RCUS $9.38
- Analyst Decision
- MTAL Hold
- RCUS Buy
- Analyst Count
- MTAL 4
- RCUS 9
- Target Price
- MTAL $12.08
- RCUS $20.86
- AVG Volume (30 Days)
- MTAL 757.6K
- RCUS 1.1M
- Earning Date
- MTAL 08-09-2025
- RCUS 08-07-2025
- Dividend Yield
- MTAL N/A
- RCUS N/A
- EPS Growth
- MTAL N/A
- RCUS N/A
- EPS
- MTAL N/A
- RCUS N/A
- Revenue
- MTAL $340,736,000.00
- RCUS $141,000,000.00
- Revenue This Year
- MTAL $18.41
- RCUS N/A
- Revenue Next Year
- MTAL $23.55
- RCUS $28.73
- P/E Ratio
- MTAL N/A
- RCUS N/A
- Revenue Growth
- MTAL 114.30
- RCUS N/A
- 52 Week Low
- MTAL $7.69
- RCUS $6.50
- 52 Week High
- MTAL $14.93
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- MTAL 60.65
- RCUS 57.71
- Support Level
- MTAL $11.94
- RCUS $8.03
- Resistance Level
- MTAL $12.09
- RCUS $9.97
- Average True Range (ATR)
- MTAL 0.09
- RCUS 0.47
- MACD
- MTAL -0.07
- RCUS 0.11
- Stochastic Oscillator
- MTAL 50.00
- RCUS 71.32
About MTAL Metals Acquisition Limited
MAC Copper Ltd is a company focused on operating and acquiring metals and mining businesses in high-quality, stable jurisdictions that are critical in the electrification and decarbonization of the world-wide economy.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.